Paper Details

  1. Home
  2. Paper Details

A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.

Author: SilbersteinStephen D

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

AVP-825 (sumatriptan nasal powder) is an FDA-approved intranasal medication delivery system for the acute treatment of migraine. AVP-825 delivers a lower dose of sumatriptan than oral or injectable formulations, which may translate into a better safety/tolerability profile. AVP-825 was well-tolerated in clinical trials and provides earlier efficacy onset than other sumatriptan formulations.
Paper Details　
Original Abstract of the Article :
AVP-825 (sumatriptan nasal powder) is an FDA-approved intranasal medication delivery system containing low-dose sumatriptan powder for acute treatment of migraine with or without aura in adults. AVP-825 utilizes unique nasal anatomy features to avoid limitations of other intranasal delivery methods....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2018.1390563

データ提供：米国国立医学図書館（NLM）

A Safer Approach: Evaluating the Safety of Sumatriptan Nasal Powder for Migraine Treatment

Migraine, a debilitating neurological disorder, can significantly impact quality of life. This review evaluates the safety and efficacy of sumatriptan nasal powder (AVP-825), a novel formulation for the acute treatment of migraine. The authors highlight the unique delivery system of AVP-825, which utilizes a breath-powered exhalation device for more efficient and localized delivery of sumatriptan. They also review the safety data from clinical trials, demonstrating a favorable safety profile with fewer side effects compared to other formulations of sumatriptan.

A Breath of Fresh Air for Migraine Treatment

This review presents a promising alternative for the treatment of migraine, highlighting the safety and efficacy of sumatriptan nasal powder (AVP-825). The authors emphasize the unique delivery system of AVP-825, which offers several advantages over traditional formulations.

Empowering Patients: Finding Relief from Migraine

The development of safer and more effective migraine treatments is a crucial step in improving the lives of those living with this debilitating condition. AVP-825, with its favorable safety profile and demonstrated efficacy, offers a new ray of hope for migraine sufferers.

Dr. Camel's Conclusion

This review underscores the importance of ongoing research and development in the field of migraine treatment. The introduction of safer and more effective therapies like AVP-825 can significantly improve the lives of those living with migraine.

Date :
  1. Date Completed 2017-12-27
  2. Date Revised 2017-12-27
Further Info :

Pubmed ID

28994319

DOI: Digital Object Identifier

10.1080/14740338.2018.1390563

Related Literature

Article Analysis
・Effects of sumatriptan nasal
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.